Vaccination to Alzheimer disease. Is it a promising tool or a blind way?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F16%3A43875597" target="_blank" >RIV/60162694:G44__/16:43875597 - isvavai.cz</a>
Alternative codes found
RIV/62156489:43410/16:43909724
Result on the web
<a href="http://www.eurekaselect.com/141335/article" target="_blank" >http://www.eurekaselect.com/141335/article</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/0929867323666160418114733" target="_blank" >10.2174/0929867323666160418114733</a>
Alternative languages
Result language
angličtina
Original language name
Vaccination to Alzheimer disease. Is it a promising tool or a blind way?
Original language description
Alzheimer disease (AD) is an irreversible neurodegenerative disorder associated with cognitive dysfunction. The disease incidence has growing tendency worldwide with strong impact on healthcare funds. The fact that there is no effective therapy makes the disorder more serious. Currently, AD manifestation can be suppressed by having impact on enzyme acetylcholinesterase: donepezil, rivastigmine, and galantamine or ionotropic glutamate NMDA receptor (memanitine). Contrary to the drugs effecting symptomatically, vaccination against amyloid plaques or neurofibrillary tangles and their precursors amyloid beta and hyperphosphorylated tau are expected to be more suitable. Huge numbers of works have been done on the issue. Unfortunately, the promising vaccines like the AN 1792 were halted during clinical trials because of adverse effects like meningoencephalitis. Monoclonal antibody specific to amyloid plaques, Bapineuzumab, was closest to the practical performance but the clinical trials were also stopped. The review summarizes facts about AD, opportunities in AD vaccination, and obstacles that limit the vaccination including reasons why the recent trials have fallen.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Medicinal Chemistry
ISSN
0929-8673
e-ISSN
—
Volume of the periodical
23
Issue of the periodical within the volume
14
Country of publishing house
AE - UNITED ARAB EMIRATES
Number of pages
10
Pages from-to
1432-1441
UT code for WoS article
000376451500003
EID of the result in the Scopus database
—